{"nctId":"NCT00088166","briefTitle":"XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors","startDateStruct":{"date":"2004-05"},"conditions":["Brain Edema","Brain Tumor"],"count":200,"armGroups":[{"label":"I","type":"EXPERIMENTAL","interventionNames":["Drug: hCRF"]},{"label":"II","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo hCRF"]}],"interventions":[{"name":"hCRF","otherNames":["XERECEPT (corticorelin acetate injection); hCRF"]},{"name":"placebo hCRF","otherNames":["XERECEPT (corticorelin acetate injection)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a primary malignant brain tumor or, if metastatic, documentation and histology (if available) of primary source of cancer.\n* Patient must have 1 or more qualifying steroid-associated side effect(s) at Baseline.\n* Patient has required administration of dexamethasone to control symptoms of peritumoral edema for at least 30 days.\n* Stable dexamethasone dose of 4-24 mg/day for at least 14 days prior to Baseline.\n* Need for administration of dexamethasone to treat peritumoral brain edema (referenced above) has been documented by MRI or comparable diagnostic technology within 21 days of Baseline.\n* Karnofsky score of \\> 50 at Screening and Baseline.\n* Capable of self-administration of subcutaneous injections twice daily for 12 weeks, or availability of assistance from caregiver.\n* Ability to provide written informed consent or, if unable to provide, have a legal guardian or representative provide written informed consent.\n* For women of childbearing potential: a negative serum pregnancy test at Screening.\n* Must be 18 years of age or older\n\nExclusion Criteria:\n\n* Ongoing or anticipated need for surgery, radiosurgery or radiation therapy or the introduction of new chemotherapeutic regime within the first 5 weeks of study enrollment. Treatment with pre-study chemotherapy may continue.\n* Concurrent enrollment in any other investigational drug or device study, or plan to enroll in such a study during the first 5 weeks of treatment.\n* Systemic steroid use for any indication other than peritumoral brain edema.\n* Use or intended use of dexamethasone as an anti-emetic during Screening or Study\n* Non-compliance with dexamethasone or anticonvulsant therapy.\n* Clinical signs and symptoms of cerebral herniation.\n* Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease which could put the patient at unusual risk for study participation.\n* Confounding previous or concurrent neurological disorders that would interfere with adequate clinical evaluation.\n* Clinically significant head injury or chronic seizure disorder, if the condition results in functional impairment or is likely to interfere with evaluations. (Maintenance anticonvulsant therapy is allowed.)\n* Central nervous system infection.\n* Pregnancy, breastfeeding and/or refusal to practice birth control while in study, for women of childbearing potential.\n* Any conditions that are considered contraindications for patients to receive niacin, e.g. liver disease (with LFTs \\> 3 times the upper limit of the norm),active peptic ulcer, arterial hemorrhage, asthma and known hypersensitivity to niacin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5","description":"The primary efficacy endpoint was the proportion of patients in each treatment group who were Responders at Week 2 and who continued to be Responders at Week 5. Responders were defined as study patients who demonstrated the following:\n\n* 50% or greater reduction in dexamethasone dose relative to Baseline\n* Overall 10-Item Neurological Examination Score unchanged or lower compared to Baseline\n* Karnofsky Score unchanged or increased relative to Baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients in Each Treatment Group Achieving 50% Reduction in Dexamethasone Usage Relative to Baseline by Week 2 Without Deterioration in Neurological Function as Measured by the 10-Item Neurological Exam and the KPS","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Who Continue to be Responders at Weeks 5 and 8","description":"• The proportion of patients in each treatment group who were Responders at Week 2 and who continued to be Responders at Weeks 5 and 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the 10-Item Neurological Examination Score at Weeks 2, 5, 8 12 and 16 (or Early Discontinuation)","description":"Change from Baseline in the 10-Item Neurological Examination Score at Weeks 2, 5, 8, 12 (or Early Study Drug Discontinuation), and 16 (or 4-week follow-up visit). Each item is scored from 0 (normal) to 4 (severely abnormal) except for speech (0-3) for a total range of 0-39. Total score for each patient was the sum of each item score. Change is calculated as the follow-up score minus the baseline score; a negative value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.3"},{"groupId":"OG001","value":"-0.1","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.9"},{"groupId":"OG001","value":"0.4","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.1"},{"groupId":"OG001","value":"0.5","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"3.1"},{"groupId":"OG001","value":"0.7","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"3.1"},{"groupId":"OG001","value":"0.8","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Karnofsky Performance Score","description":"Change from Baseline in the Karnofsky Performance Score at Weeks 2, 5, 8, 12 and 16.The Karnofsky score runs from 100 to 0, where 100 is \"perfect\" health and 0 is death. Although practitioners occasionally assign performance scores in between standard intervals of 10 as follows:\n\n100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.\n\n50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.\n\n20 - Very sick; hospital admission necessary; active supportive treatment nec","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"7.4"},{"groupId":"OG001","value":"-2.2","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"9.6"},{"groupId":"OG001","value":"-2.6","spread":"8.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"10.3"},{"groupId":"OG001","value":"-3.2","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"10.1"},{"groupId":"OG001","value":"-3.3","spread":"10.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"10.1"},{"groupId":"OG001","value":"-3.6","spread":"10.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the FACT-Br Quality of Life Results","description":"The FACT-Br Quality of Life Questionnaire was self-administered at Baseline, Weeks 5 and 12 (or upon Early SDD), and at the post-treatment 4-week follow-up visit (Week 16 and/or any unscheduled 4-week Follow-up).FACT-Br is a reliable and valid 50-item measure that includes FACT-G (27 items) and a brain subscale (23 items) to assess health-related quality of life in brain tumor patients. Each inventory question is scored from 0 (worst possible QOL) to 4 (best possible QOL)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"17.5"},{"groupId":"OG001","value":"-2.2","spread":"15.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"20.3"},{"groupId":"OG001","value":"-1.9","spread":"20.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"01.7","spread":"20.9"},{"groupId":"OG001","value":"-5.9","spread":"20.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Myopathy Assessment Results at Week 12 (or Early Study Drug Discontinuation) and Week 16 (or 4-week Follow-up Visit)","description":"Myopathy, using Kendall Myopathy Scale, was assessed at Baseline, Week 12 (or upon Early SDD), and at the post-treatment 4-week follow-up visit (Week 16 and/or any unscheduled 4-week Follow-up). The Kendall Myopathy Scale is a 10 point scale where 10 represents holding test position against strong pressure (best) and 0 represents no contraction palpable (worst).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.8"},{"groupId":"OG001","value":"-0.2","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.7"},{"groupId":"OG001","value":"-0.3","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Maximum Percent Reduction in Dexamethasone Usage Relative to Baseline Achieved During the Study","description":"The maximum reduction in dexamethasone usage at any time during the study. Dexamethasone dosage was assessed at Weeks 0, 2, 5, 8, 12 and 16.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.7","spread":"21.8"},{"groupId":"OG001","value":"-51.4","spread":"21.5"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Discontinued Study Drug Prior to the End of Week 5","description":"Numbers of patients who discontinued prior to the Week 5 assessment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":101},"commonTop":["Flushing","Headache","Fatigue","Oedema peripheral","Neoplasm progression"]}}}